MedPath

DNA Methylation Combined With Artificial Intelligence Imaging to Identify Lung Nodules

Recruiting
Conditions
Lung Cancer Diagnosis
Interventions
Diagnostic Test: DNA methylation joint AI imaging
Registration Number
NCT06220305
Lead Sponsor
The First Affiliated Hospital with Nanjing Medical University
Brief Summary

Lung cancer is the leading cause of cancer deaths,and the key to reducing mortality in lung cancer patients is early diagnosis and treatment.Currently,peripheral blood DNA methylation is a novel in vitro molecular marker for tumors.Meanwhile artificial intelligence diagnostic system can further improve the diagnostic ability.The purpose of this study is to apply the overall DNA methylation level (i.e.,methylation profile) and the altered methylation degree of specific genes as tumor diagnostic indexes,and combined with the artificial intelligence imaging technology for the early and accurate diagnosis of lung cancer,to achieve the early detection,diagnosis,and treatment of lung cancer,and to effectively reduce the mortality rate of lung cancer.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
100
Inclusion Criteria
  • (1) Patients with pulmonary nodules diagnosed by imaging;
  • (2) No contraindications to blood collection;
  • (3) Voluntary completed DNA methylation testing;
  • (4) Signed informed consent and performed all the study mandated procedures.
Exclusion Criteria
  • (1) Pregnant or lactating(6 months) women;
  • (2) History of malignancy or known malignancy or precancerous lesions or known tuberculosis within 3 years;
  • (3) Autoimmune system disorders;
  • (4) Undergoing any diagnostic puncture therapy, such as percutaneous lung biopsy, transbronchial, pre-enrollment biopsy, or surgical procedures (within 6 months); (5) Recipients of organ transplants or prior non-autologous (allogeneic) bone marrow transplants or stem cell transplants; (6) Received antibiotic therapy within 14 days or applied a drug that elevates white blood cells within 45 days prior to the blood draw.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Pulmonary Nodule GroupDNA methylation joint AI imagingpatient conform pulmonary nodules on CT images
Primary Outcome Measures
NameTimeMethod
Efficacy of early diagnosis of benign and malignant lung nodules by blood DNA methylation results combined with AI imaging10 months

Construction of a diagnostic model for DNA methylation combined with AI imaging. Comparing the results of the model with pathologic diagnosis, including sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV).

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Jiangsu Province Hospital

🇨🇳

Nanjing, Jiangsu, China

© Copyright 2025. All Rights Reserved by MedPath